Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2019; 9(10):2843-2855. doi:10.7150/thno.33727 This issue Cite

Research Paper

Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease

Jiulong Zhao1,2‡, Wei Gao3‡, Xiaojun Cai1,3,✉, Jiajia Xu2, Duowu Zou2,✉, Zhaoshen Li2, Bing Hu3,✉, Yuanyi Zheng1,✉

1. Shanghai Institute of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233 (China)
2. Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433 (China)
3. Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233 (China)
‡These authors contributed equally to this work.

✉ Corresponding authors: Dr. Xiaojun Cai, c1x2j34com; Prof. Duowu Zou, zdw_picom; Prof. Bing Hu, binghu_stephencom; Prof. Yuanyi Zheng, zhengyuanyicom

Citation:
Zhao J, Gao W, Cai X, Xu J, Zou D, Li Z, Hu B, Zheng Y. Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease. Theranostics 2019; 9(10):2843-2855. doi:10.7150/thno.33727. https://www.thno.org/v09p2843.htm
Other styles

File import instruction

Abstract

Graphic abstract

The overproduction of reactive oxygen species (ROS) is linked to inflammatory bowel disease (IBD) and causes oxidative damage to DNA, proteins, and lipids. These ROS promote the initiation and progression of ulcerative colitis (UC). This study proposes a unique concept of nanomaterials with intrinsic enzyme-like activity (nanozymes) to mediate catalytic nanotherapy for IBD.

Methods: We first synthesized manganese Prussian blue nanozymes (MPBZs) with multi-enzyme activity. A dextran sulfate sodium (DSS)-induced mouse model of colitis was built. The ROS scavenging capacity and anti-inflammatory effects of the MPBZs were investigated.

Results: As a proof of concept, MPBZs with multi-enzyme activity were constructed of variable valence elements (Mn and Fe) via a facile and efficient strategy. Due to the increased intestinal permeability and positively charged surfaces of inflamed mucosa in murine colitis, the prepared MPBZs with nanoscale sizes and negative charges preferentially accumulated at inflamed sites after oral administration. Importantly, MPBZs mediated catalytic nanotherapy for IBD in mice via a primary effect on the toll-like receptor signaling pathway without adverse side effects.

Conclusion: MPBZs with multi-enzyme activity were constructed to treat IBD. This nanozyme-based approach is a promising strategy for catalytic nanotherapy in patients with colonic IBD.

Keywords: nanozyme, multi-enzyme activity, reactive oxygen species, inflammatory bowel disease, manganese Prussian blue

Citation styles

APA
Zhao, J., Gao, W., Cai, X., Xu, J., Zou, D., Li, Z., Hu, B., Zheng, Y. (2019). Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease. Theranostics, 9(10), 2843-2855. https://doi.org/10.7150/thno.33727.

ACS
Zhao, J.; Gao, W.; Cai, X.; Xu, J.; Zou, D.; Li, Z.; Hu, B.; Zheng, Y. Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease. Theranostics 2019, 9 (10), 2843-2855. DOI: 10.7150/thno.33727.

NLM
Zhao J, Gao W, Cai X, Xu J, Zou D, Li Z, Hu B, Zheng Y. Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease. Theranostics 2019; 9(10):2843-2855. doi:10.7150/thno.33727. https://www.thno.org/v09p2843.htm

CSE
Zhao J, Gao W, Cai X, Xu J, Zou D, Li Z, Hu B, Zheng Y. 2019. Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease. Theranostics. 9(10):2843-2855.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use